Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Change in Accured Expenses (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Change in Accured Expenses for 11 consecutive years, with -$3.2 million as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses fell 216.71% to -$3.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.5 million through Dec 2025, up 5.73% year-over-year, with the annual reading at -$2.5 million for FY2025, 5.73% up from the prior year.
  • Change in Accured Expenses hit -$3.2 million in Q4 2025 for Voyager Therapeutics, down from $2.8 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $5.8 million in Q4 2023 to a low of -$9.3 million in Q1 2024.
  • Historically, Change in Accured Expenses has averaged -$131400.0 across 5 years, with a median of $422500.0 in 2021.
  • Biggest five-year swings in Change in Accured Expenses: soared 1065.84% in 2022 and later crashed 7527.05% in 2024.
  • Year by year, Change in Accured Expenses stood at -$423000.0 in 2021, then plummeted by 1007.33% to -$4.7 million in 2022, then soared by 223.21% to $5.8 million in 2023, then crashed by 52.71% to $2.7 million in 2024, then plummeted by 216.71% to -$3.2 million in 2025.
  • Business Quant data shows Change in Accured Expenses for VYGR at -$3.2 million in Q4 2025, $2.8 million in Q3 2025, and $3.0 million in Q2 2025.